Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: The case for studies in previously treated patients Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Small Cell
  • Lung Neoplasms

abstract

  • Over the past 2 decades, phase II trials in SCLC have failed in their primary task of effectively identifying agents that warrant further clinical study and rejecting inactive agents. If only previously treated patients had been entered into these trials, no useful agent would have been missed provided that a lower observed response rate had been used as evidence of antitumor activity. We propose a two-stage sequential study design, entering previously treated patients, for future phase II trials in SCLC.

publication date

  • December 1992

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 1311028

Additional Document Info

start page

  • 484

end page

  • 98

volume

  • 10

number

  • 3